Lilly study: 1 in 5 Alzheimer's patients misdiagnosed

Back to TopCommentsE-mailPrintBookmark and Share

Nearly one in five patients diagnosed with Alzheimer’s disease doesn’t actually have the memory-sapping malady, according to a new study sponsored by Eli Lilly and Co.

The study results, which will be released Monday afternoon, are part of Indianapolis-based Lilly’s campaign to get the federal Medicare program to pay for use of its imaging agent Amyvid, which received U.S. market approval last year.

Wall Street analysts do not expect Amyvid to be a blockbuster product for Lilly. For example, Goldman Sachs analyst Jami Rubin predicts its sales will total just $80 million annually by 2017.

But Amyvid could be a huge help in Lilly’s efforts to bring drugs to market to treat Alzheimer’s. Since there are currently no effective treatments for the disease, any drug that did help with treatment would be an instant blockbuster.

Lilly’s experimental drug solanezumab could have sales topping $4 billion annually if it proves effective in patients with mild Alzheimer’s disease. The drug failed its clinical trials last year when tested in a mix of mild and moderate Alzheimer’s patients, but it showed encouraging results in patients with only mild Alzheimer’s disease.

Lilly officials are going to run a new trial for solanezumab focusing only on mild Alzheimer’s patients—or perhaps even patients with a precursor to Alzheimer’s, referred to as mild cognitive impairment or prodromal Alzheimer’s.

The only way to identify such patients is by using a special kind of imaging test that will show deposits of a protein called amyloid—which is one of two telltale signs of Alzheimer’s disease. The imaging test is called PET, or positron emission tomography.

Before Amyvid, however, the only way to view these plaques was during an autopsy. Now, doctors and researchers can look at amyloid plaques in living patients.

“Amyloid PET imaging in my opinion may be the most important recent advance in AD therapeutic research. … It has allowed us to have complete confidence in the diagnosis of AD dementia, something that was lacking before we used amyloid imaging,” said Dr. Paul Aisen, professor of neurosciences at the University of California-San Diego, during a Jan. 30 meeting of the Medicare Evidence Development & Coverage Advisory Committee.

Aisen, whose research has been behind some of the high-profile failures of experimental drugs aimed at Alzheimer’s, has been in discussions with Lilly on a new research project. He expects that some of the drugs that have failed to be effective in patients with full-blown Alzheimer’s will be effective in earlier stages of the disease.

“Treatments that are only marginally effective in dementia are going to be highly effective in preclinical AD, I predict, and that will mean that eventually we will be screening the population with amyloid PET scans or spinal taps in their 50s to … prevent the development of AD dementia,” Aisen said.

Not everyone agrees with him. For example, panelists on the Medicare advisory commission pointed out that Amyvid has not been directly studied as a predictor of Alzheimer’s disease and that 20 percent to 30 percent of patients who do have amyloid plaques in their brain show no symptoms of cognitive impairment at all.

But if Aisen is right, Amyvid might get wider usage—and more sales—than analysts are currently predicting.

Medicare, even if it pays for patients to use Amyvid, might save the roughly $38,000 it costs per year to treat an Alzheimer’s patient—at least for the 20 percent of them who have been misdiagnosed.

But most significantly for Lilly and other drugmakers, it could open up a field of customers far larger than the 5.2 million Americans that currently have the disease—or even than the 7.1 million expected to have it by 2025.

An international survey conducted in 2011 by researchers at the Harvard School of Public Health found that two-thirds of adults would take a predictive Alzheimer's test were one made available to them.

Lilly is expressly not asking for such widespread testing—at this point. But if it were to occur, the number of patients identified with Alzheimer’s and other forms of dementia could be enormous.

“This study underscores the importance of using objective tools, such as amyloid PET imaging, in addition to clinical assessment as part of a physician’s diagnostic evaluation of patients with cognitive decline,” said Michael Witte, a clinical research scientist at Lilly, who was the lead author of the study on Amyvid released Monday.

That study, conducted in partnership with the Indiana University School of Medicine’s neuroscience institute, tested 199 patients, age 55 or older, who had been diagnosed with either mild or moderate Alzheimer’s disease. Of those patients, 35 of them, or 18 percent, showed few or no amyloid plaques when given a PET scan using Amyvid--meaning they did not actually have Alzheimer's disease.


  • Alzheimer's Meds
    Greater emphasis on relief of those with this affliction today should be focused on for the benefit of these victims and their Loved ones in order to obtain quality of life for their years remaining since we are years from the cure in today's funding priorities.
  • What>?
    Anything that can help with this disease should be approved!!! Leave it to the government to delay efforts of diagnose or treatment. I lost my father to this awful disease and if you havent been through it then its very difficult to understand how distructive it is not only to the person but the entire family. Please contact your state and local politicians and incourage them to vote for any and all progressive AD help.

Post a comment to this story

We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
You are legally responsible for what you post and your anonymity is not guaranteed.
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
Subscribe to IBJ
  1. How much you wanna bet, that 70% of the jobs created there (after construction) are minimum wage? And Harvey is correct, the vast majority of residents in this project will drive to their jobs, and to think otherwise, is like Harvey says, a pipe dream. Someone working at a restaurant or retail store will not be able to afford living there. What ever happened to people who wanted to build buildings, paying for it themselves? Not a fan of these tax deals.

  2. Uh, no GeorgeP. The project is supposed to bring on 1,000 jobs and those people along with the people that will be living in the new residential will be driving to their jobs. The walkable stuff is a pipe dream. Besides, walkable is defined as having all daily necessities within 1/2 mile. That's not the case here. Never will be.

  3. Brad is on to something there. The merger of the Formula E and IndyCar Series would give IndyCar access to International markets and Formula E access the Indianapolis 500, not to mention some other events in the USA. Maybe after 2016 but before the new Dallara is rolled out for 2018. This give IndyCar two more seasons to run the DW12 and Formula E to get charged up, pun intended. Then shock the racing world, pun intended, but making the 101st Indianapolis 500 a stellar, groundbreaking event: The first all-electric Indy 500, and use that platform to promote the future of the sport.

  4. No, HarveyF, the exact opposite. Greater density and closeness to retail and everyday necessities reduces traffic. When one has to drive miles for necessities, all those cars are on the roads for many miles. When reasonable density is built, low rise in this case, in the middle of a thriving retail area, one has to drive far less, actually reducing the number of cars on the road.

  5. The Indy Star announced today the appointment of a new Beverage Reporter! So instead of insightful reports on Indy pro sports and Indiana college teams, you now get to read stories about the 432nd new brewery open or some obscure Hoosier winery winning a county fair blue ribbon. Yep, that's the coverage we Star readers crave. Not.